Zeo ScientifiX and Pluri Agree U.S. Partnership; Pluri Expected to Own 50%
The partnership will expand U.S. manufacturing and commercialization of regenerative medicine products, combining Zeo ScientifiX’s biologics business and physician network with Pluri’s cell-expansion technology. At closing, Pluri is expected to own 50% of Zeo ScientifiX.